Richard I. Eisenstadt This is Me

Education

 View all 9 references Web References

1. 1. heraldsun.com: Venture capital hurdles are higher

   www.herald-sun.com/business/21 - [Cached]

   Published on: 7/26/2005   Last Visited: 7/27/2005

   Part of the problem for local companies is that venture capitalists currently have a lot of late-stage investment options, said Richard Eisenstadt, chief financial officer at Tranzyme. With the public markets tepid, larger biotech companies are seeking venture capital rather than going public, he said.
   
   That makes things difficult for smaller, younger companies in areas like the Triangle.
   
   "There are safer bets and promises of quicker returns available to the venture community," Eisenstadt said.
   
   But earlier stage companies still are securing funds.
   ...
   A group of international investors gave momentum to Tranzyme's financing round, Eisenstadt said. The company started out seeking $15 million and had offers of $40 million to $45 million on the table before settling on its final $32 million round, he said.
   
   Raising that kind of money "really helps senior management focus on the development of the product rather than spending most of their time trying to raise money," he said.

2. 2. Tranzyme and Neokimia Announce US $6 Million in New Financing in Conjunction with Their Merger

   biz.yahoo.com/bw/031218/185020 - [Cached]

   Published on: 12/18/2003   Last Visited: 12/18/2003

   Richard I. Eisenstadt, MBA
   
   Vice President, Finance, Tranzyme, Inc.
   
   919-597-6623; reisenstadt@tranzyme.com

3. 3. heraldsun.com: Venture capital hurdles are higher

   www.heraldsun.com/business/21- - [Cached]

   Published on: 7/26/2005   Last Visited: 7/27/2005

   Part of the problem for local companies is that venture capitalists currently have a lot of late-stage investment options, said Richard Eisenstadt, chief financial officer at Tranzyme. With the public markets tepid, larger biotech companies are seeking venture capital rather than going public, he said.
   
   That makes things difficult for smaller, younger companies in areas like the Triangle.
   
   "There are safer bets and promises of quicker returns available to the venture community," Eisenstadt said.
   
   But earlier stage companies still are securing funds.
   ...
   A group of international investors gave momentum to Tranzyme's financing round, Eisenstadt said. The company started out seeking $15 million and had offers of $40 million to $45 million on the table before settling on its final $32 million round, he said.
   
   Raising that kind of money "really helps senior management focus on the development of the product rather than spending most of their time trying to raise money," he said.